Literature DB >> 8339257

Potentiation of a three drug chemotherapy regimen by radiation.

J A Koutcher1, A A Alfieri, R L Stolfi, M L Devitt, J R Colofiore, L D Nord, D S Martin.   

Abstract

The combination of N-(phosphonacetyl)-L-aspartate, 6-methylmercaptopurine, and 6-aminonicotinamide has been shown to be an effective antineoplastic regimen and also to enhance the effects of other chemotherapeutic agents. The mechanism of action of this combination of drugs is not known definitively, but one possible mechanism is biochemical modulation of energy metabolism and inhibition of production of tumor ATP. Tumor-bearing mice were treated with N-(phosphonacetyl)-L-aspartate, followed 17 h later by 6-methylmercaptopurine and 6-aminonicotinamide. 31P nuclear magnetic resonance spectroscopic studies demonstrated a significant depletion of high energy phosphates at 10 h post-6-methylmercaptopurine and 6-aminonicotinamide. The addition of radiation at this time was shown to induce a significantly longer tumor growth delay and a greater number of regressions (including durable complete regressions) than either chemotherapy or radiation alone. The combination of chemotherapy and radiation was found to be supra-additive compared to the antineoplastic effects of either modality administered separately, without a measurable increase in host toxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339257

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

Review 1.  Applications of magnetic resonance in model systems: cancer therapeutics.

Authors:  J L Evelhoch; R J Gillies; G S Karczmar; J A Koutcher; R J Maxwell; O Nalcioglu; N Raghunand; S M Ronen; B D Ross; H M Swartz
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  Niacin analogue, 6-Aminonicotinamide, a novel inhibitor of hepatitis B virus replication and HBsAg production.

Authors:  Fang Ren; Xiao Yang; Zhong-Wen Hu; Vincent Kam Wai Wong; Hong-Yan Xu; Ji-Hua Ren; Shan Zhong; Xiao-Jiong Jia; Hui Jiang; Jie-Li Hu; Xue-Fei Cai; Wen-Lu Zhang; Fang-Long Yao; Hai-Bo Yu; Sheng-Tao Cheng; Hong-Zhong Zhou; Ai-Long Huang; Betty Yuen Kwan Law; Juan Chen
Journal:  EBioMedicine       Date:  2019-10-31       Impact factor: 8.143

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.